Turbine, a Budapest, Hungary-based company developing a cell behavior simulation platform, raised €20M in Series A funding.
The round was co-led by Mercia and MSD Global Health Innovation Fund, with participation from Day One Capital, Accel, Delin Ventures, and XTX Ventures. In conjunction with the financing, MSD GHI Fund and Mercia Asset Management have delegated members to Turbine’s new Board.
The company intends to use the funds to drive its first-in-class programs targeting DNA Damage Repair.
Founded by Kristof Szalay, Daniel Veres, and Szabolcs Nagy (CEO), Turbine has developed and validated the Simulated Cell, a proprietary and platform that runs billions of simulations prior to ever initiating preclinical development guiding real-life experiments with invaluable biological insights. This improves the likelihood of success for novel therapies and allows existing assets to be optimally targeted to patients most likely to benefit from them. Its technology leverages artificial intelligence (AI) to build a constantly evolving, predictive simulation of cellular signaling. Simulations have already been validated from target discovery to patient stratification and life cycle management in collaborations with multiple big pharma companies.
FinSMEs
22/11/2022